ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

ESMO 2024 Summary: Updates in the Treatment of MCL

2024 ESMO Annual Meeting Insights Hub

G. Hess

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Top 5 Lymphoma Abstracts From ASH

Jennifer Amengual

EZH2 Inhibition in FL: Overview and Analysis of the SYMPHONY-1 Trial

Northwestern Medicine Oncology and Hematology

L. Gordon

The Next Frontier of Targeted Therapy in Lymphoma

UChicago Medicine

K. Maddocks

UChicago Medicine Best of ASCO® 2024: HL, DLBCL, MCL

UChicago Medicine Annual Practice Updates in Hematology and Oncology

A. Rojek

Key Lymphoma Updates From ASH

Memorial Sloan Kettering Cancer Center

P. Torka

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

CLL and MCL: Experts Discuss the Use of Pirtobrutinib

MyCancerHaven

R. Vij, G. Shouse

Practical Updates on Advances in CLL and MCL

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

E. Chong

Standards of Care and Future Directions in MCL

Martin Dreyling

Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas

University of Colorado Division of Hematology

M. Kamdar

When Not to Watch and Wait: Emerging Strategies in the Treatment of …

Indy Hematology Review

M. Williams

EHA 2024 Insights: Intrathecal Rituximab + Dex for Refractory Sanctu…

Insights from 2024 EHA Annual Meeting

M. Salamoon

Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN…

Fox Chase Cancer Center

S. Nakhoda

Caring for Patients With Lymphoma: Using Guidelines to Improve Quali…

Yale Cancer Center

S. Huntington, E. Winer

Immune Effector Cell Therapy for Lymphoid Malignancies: What to Do a…

Indy Hematology Review

T. Phillips

EHA 2024 Insights: Zanubrutinib vs. Acalabrutinib in B-cell Malignan…

Insights from 2024 EHA Annual Meeting

T. Munir

Update on Cellular Therapy in Lymphoma

Total Health

B. Randolph